Latest Administration News

ANZ Group Holdings Limited has updated its interim dividend details, confirming an 83-cent payout per share, partially franked at 70%, payable on July 1, 2025. The bank also outlined its Dividend Reinvestment and Bonus Security Plans with shares priced at AUD 28.89.

Fintech Chain Limited reported a 24% revenue increase to RMB55.9 million for FY2025 driven by new SaaS products, yet it remains in the red with a net loss of RMB4.8 million. The company has also applied for delisting from the ASX.

Helios Energy Limited has come under ASX compliance scrutiny after late lodgement of director interest notices, raising questions about its disclosure practices and governance.

Papyrus Australia reported a $52,000 operating cash outflow for April 2025 but bolstered its liquidity with $239,000 in financing inflows, extending its funding runway to over a year.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

Mount Hope Mining Limited has announced a non-renounceable pro-rata Loyalty Option Offer to raise approximately $103,125, aiming to bolster exploration funding and reward shareholder loyalty.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

Pacific Edge Limited reported a resilient FY25 performance despite losing Medicare coverage for its Cxbladder tests in the US, announcing a $20 million equity raise to support commercialization and growth.

8I Holdings Limited reported a net loss of S$1.09 million for FY2025, impacted by a sharp decline in investment gains due to global market volatility and new U.S. tariffs. The Group remains focused on a conservative, value-driven investment strategy despite challenging conditions.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.

Epsilon Healthcare has emerged from Administration, securing expanded medicinal cannabis manufacturing permits and launching a new pharmacy brand as part of a strategic turnaround and growth plan.